Clinical

The analysis suggests the marker could be used to screen patients for potential immunotherapy.

Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version.

A payer discusses medical exceptions processes and triggers for a class review for drugs in women’s health, along with wraparound programs for uterine fibroids and endometriosis.

A medical professional explains the many facets of the prior authorizations process for drugs in women’s health.

Ryan Haumschild, PharmD, MBA, MS, provides background on the Affordable Care Act (ACA) within the scope of women’s health, including specific mandates on contraceptives.

This new study, from Taiwan, investigated how menopause affects ventricular structure and function and its possible impact on heart failure among women.

Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.

This new study from Canada compared outcomes in patients living with type 1 diabetes who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting.

Dr Slipczuk concludes our discussion by detailing healthcare disparities commonly seen within ASCVD treatment.

A cardiology expert considers the future of lipid management within health systems and ways they can improve engagement from all parties.

Dr Slipczuk explores quality metrics, elaborating on ways to improve and align them with the latest cardiology treatment guidelines and payer considerations.

The findings from the study indicate that higher genetic risk score for Alzheimer disease (AD) are associated with cognitive declines in patients with Parkinson disease (PD), while higher genetic risk scores for PD signify an increased risk of PD, albeit with slower clinical progression after diagnosis.

Results of a randomized controlled trial found supplementation with vitamin D among those at risk for type 2 diabetes (T2D) did not prevent onset of the disease.

Angel Qin, MD, clinical assistant professor of medicine at the University of Michigan, discusses the need for more clinical trials in small cell lung cancer and for more patients to qualify for trials.

Surveys of patients and oncologists found discrepancies between patient experiences and oncologist perceptions of those experiences during a nonmedical switch to trastuzumab biosimilars.

Recurrence is common in patients with distal cholangiocarcinoma, even after curative surgical resection. In a recent study, postoperative adjuvant therapy correlated with improved survival, but only in certain patients.

Multiple myeloma has historically been considered a chronic disease, even as newer treatments have greatly improved rates of survival for the disease.

Citing outbreaks of Clostridioides difficile infection in both America and Europe, the researchers emphasized the need for more effective treatments.

The approvals were announced by Bristol Myers Squibb (BMS), maker of the 2 immunotherapy treatments approved for 1 combination: nivolumab (Opdivo), the first approved PD-1 immune checkpoint inhibitor, and ipilimumab (Yervoy), which activates the immune system by targeting CTLA-4.

Using a 6-month lagged CD4/CD8 ratio, researchers found a ratio of 0.30 was associated with a 24% increased risk of any incident cancer among people living with HIV, compared with a ratio of 0.80.

US adults who survived a COVID-19 infection are more likely than individuals who were not infected with COVID-19 to develop incident conditions attributable to the virus.

Investigators in Spain evaluated symptoms and comorbidities associated with eosinophilic esophagitis.

The researchers found that extramedullary disease at diagnosis was significantly more common in patients with bone marrow fibrosis.

Data to be presented next week during the American Society of Clinical Oncology Annual Meeting show that for every 10% increase in public welfare spending, there was a 4.55% narrowing of the 5-year overall survival (OS) disparity between Black and White patients with cancer.

As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents.